Miesbach, W;
Halimeh, S;
Platokouki, H;
Podolak-Dawidziak, M;
Zdziarska, J;
Korczowski, B;
Chowdary, P;
Austin, S;
Millar, C;
Alamelu, J;
et al.
Miesbach, W; Halimeh, S; Platokouki, H; Podolak-Dawidziak, M; Zdziarska, J; Korczowski, B; Chowdary, P; Austin, S; Millar, C; Alamelu, J; Rogosch, T; Pabinger, I
(2024)
An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand disease.
Haemophilia, 30 (1).
pp. 236-240.
ISSN 1365-2516
https://doi.org/10.1111/hae.14868
SGUL Authors: Austin, Steve
Item Type: |
Article
|
Additional Information: |
© 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
Keywords: |
Humans, von Willebrand Diseases, von Willebrand Factor, Factor VIII, Patients, 1103 Clinical Sciences, Cardiovascular System & Hematology |
SGUL Research Institute / Research Centre: |
Academic Structure > Institute of Medical, Biomedical and Allied Health Education (IMBE) |
Journal or Publication Title: |
Haemophilia |
ISSN: |
1365-2516 |
Language: |
eng |
Publisher License: |
Creative Commons: Attribution-Noncommercial 4.0 |
Projects: |
Project ID | Funder | Funder ID |
---|
UNSPECIFIED | CSL Behring | UNSPECIFIED |
|
PubMed ID: |
38030954 |
Web of Science ID: |
WOS:001111617700001 |
 |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/116026 |
Publisher's version: |
https://doi.org/10.1111/hae.14868 |
Statistics
Item downloaded times since 22 Jan 2024.
Actions (login required)
 |
Edit Item |